Latest OLMA reports update at 2024-05-08: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Olema Pharmaceuticals OLMA

$ 9.69 0.73%

Olema Pharmaceuticals Balance Sheet 2011-2024 | OLMA

Annual Balance Sheet Olema Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-66.1 M	-21.1 M	-10.5 M	-339 M	-68 K	-3.15 M	-	-	-	-	-	-	-
Long Term Debt	1.43 M	1.55 M	2.36 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	988 K	1.02 M	931 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	9.35 M	9.35 M	-	-	-	-	-	-	-
Total Current Liabilities	21.6 M	16.5 M	9.02 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	23 M	18.1 M	11.4 M	4.58 M	10.7 M	9.55 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-306 M	-209 M	-104 M	-	-10.8 M	-6.45 M	-	-	-	-	-	-	-
Total Assets	277 M	216 M	296 M	343 M	132 K	3.27 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	68.5 M	23.7 M	13.8 M	339 M	-	-	-	-	-	-	-	-	-
Book Value	254 M	198 M	285 M	338 M	-10.6 M	-6.28 M	-	-	-	-	-	-	-
Total Shareholders Equity	254 M	198 M	285 M	338 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Olema Pharmaceuticals

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	1.15 M	1.43 M	1.7 M	1.21 M	1.38 M	1.55 M	1.75 M	2.01 M	2.16 M	2.36 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	27.4 M	23 M	17.7 M	16 M	20.8 M	18.1 M	14.3 M	14.3 M	12.3 M	11.4 M	8.9 M	8.15 M	5.28 M	4.58 M	4.58 M	4.58 M	4.58 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-337 M	-306 M	-279 M	-257 M	-237 M	-209 M	-183 M	-160 M	-127 M	-104 M	-82.6 M	-64.8 M	-48.4 M	-33.1 M	-33.1 M	-33.1 M	-33.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	264 M	277 M	293 M	178 M	196 M	216 M	232 M	251 M	277 M	296 M	310 M	322 M	331 M	343 M	343 M	343 M	343 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	33.7 M	68.5 M	117 M	35 M	40.9 M	23.7 M	26.8 M	24.5 M	21.5 M	13.8 M	25.6 M	50.4 M	47.9 M	339 M	339 M	339 M	339 M	68 K	-	-	-	3.15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	236 M	254 M	275 M	162 M	175 M	198 M	218 M	236 M	265 M	285 M	301 M	314 M	326 M	338 M	338 M	338 M	338 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	236 M	254 M	275 M	162 M	175 M	198 M	218 M	236 M	265 M	285 M	301 M	314 M	326 M	338 M	338 M	338 M	338 M	-10.6 M	-	-	-	-8.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency